Small Molecules

28 Aug 2022 Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian
27 Aug 2022 Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)
27 Aug 2022 Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
25 Aug 2022 Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP™ Protein Degrader
25 Aug 2022 Tachyon Receives IND Clearance from FDA to Develop Novel KDM4 Inhibitor TACH101 for Advanced Solid Tumors
23 Aug 2022 K36 Therapeutics Announces FDA Clearance of Investigational New Drug Application and Formation of Clinical Advisory Board for Lead Program KTX-1001
23 Aug 2022 Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease
23 Aug 2022 CSL Vifor and Travere Therapeutics announce EMA has accepted for review the Conditional Marketing Authorization application for sparsentan for the treatment of IgA Nephropathy
23 Aug 2022 Quizartinib Marketing Authorization Application Validated by EMA for Treatment of Adult Patients with Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia
22 Aug 2022 Vaderis Therapeutics AG Emerges from Stealth and Announces Initiation of Clinical Proof-of-Concept Trial in HHT
22 Aug 2022 Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option
19 Aug 2022 Accutar Biotechnology Receives NMPA Clearance of IND Application for AC0176 in Prostate Cancer
19 Aug 2022 BridgeBio Pharma Announces Dosing of First Patient in Phase 1 Trial of BBP-671, a Potential Best-In-Class Treatment for Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA)
19 Aug 2022 Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate
18 Aug 2022 CG Pharmaceuticals Announces First Patient Dosed in Phase 1b/2 Study Evaluating Ivaltinostat for the Treatment of Pancreatic Adenocarcinoma
18 Aug 2022 European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myeloma
18 Aug 2022 Valo Health Announces First Patient Dosed in the OPL-0401 Phase 2 study of an oral ROCK1/2 inhibitor for the Treatment of Non-Proliferative Diabetic Retinopathy
18 Aug 2022 US FDA accepts new drug application for GSK’s momelotinib for the treatment of myelofibrosis
18 Aug 2022 U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant
18 Aug 2022 Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader
17 Aug 2022 Blueprint Medicines Announces Positive Top-line Results from PIONEER Trial of AYVAKIT® (avapritinib) in Patients with Non-Advanced Systemic Mastocytosis Achieving Primary and All Key Secondary Endpoints
17 Aug 2022 Sanofi provides update on amcenestrant clinical development program
16 Aug 2022 Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958
16 Aug 2022 Bridge Biotherapeutics Receives FDA Authorization to Proceed with Phase 2 Study of BBT-877
16 Aug 2022 Daewoong Pharmaceutical Announces US FDA Clearance of IND Application for DWP213388, First-in-class Irreversible Oral Dual Acting inhibitor for Autoimmune Diseases

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up